Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82

CG Oncology, Inc.

CG Oncology, Inc.

CGON

0.00

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ: CGON) with a Buy and raises the price target from $77 to $82.